A recent publication in "Cancer Discovery" reviewed Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) spectrum of responses to platinum and PARPi therapy, exploring the genomic and clinical features that may lead to different responses, and investigates the mechanisms of resistance.